Stockscreener 앱 받기
83.25
0.92%
-0.77
전일 마감가:
$84.02
열려 있는:
$83.14
하루 거래량:
3.27M
Relative Volume:
2.60
시가총액:
$4.02B
수익:
-
순이익/손실:
$-38.99M
주가수익비율:
-27.78
EPS:
-2.9966
순현금흐름:
$-24.94M
1주 성능:
+4.09%
1개월 성능:
+9.17%
6개월 성능:
+85.74%
1년 성능:
+99.40%
1일 변동 폭
$82.41
$85.14
1주일 범위
$78.48
$86.67
52주 변동 폭
$39.41
$86.67
Soleno Therapeutics Inc Stock (SLNO) Company Profile
명칭
Soleno Therapeutics Inc
전화
650-213-8444
주소
100 MARINE PARKWAY, SUITE 400, REDWOOD CITY, CA
SLNO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SLNO
Soleno Therapeutics Inc
|
83.25 | 4.02B | 0 | -38.99M | -24.94M | -2.9966 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.30 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
521.00 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.83 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
560.14 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
241.20 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Soleno Therapeutics Inc Stock (SLNO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-05 | 재개 | Stifel | Buy |
| 2024-12-02 | 재확인 | Robert W. Baird | Outperform |
| 2024-12-02 | 재확인 | Stifel | Buy |
| 2024-09-03 | 개시 | H.C. Wainwright | Buy |
| 2024-05-10 | 개시 | Robert W. Baird | Outperform |
| 2024-02-05 | 개시 | Piper Sandler | Overweight |
| 2024-01-23 | 개시 | Stifel | Buy |
| 2023-11-21 | 재개 | Guggenheim | Buy |
| 2020-09-29 | 개시 | Guggenheim | Buy |
| 2020-01-10 | 개시 | Craig Hallum | Buy |
| 2019-12-23 | 개시 | Oppenheimer | Outperform |
| 2018-02-13 | 재확인 | Maxim Group | Buy |
모두보기
Soleno Therapeutics Inc 주식(SLNO)의 최신 뉴스
Soleno stock maintains Overweight rating at Piper Sandler on VYKAT XR outlook - Investing.com India
Trend Tracker for (SLNO) - news.stocktradersdaily.com
High Growth Tech Stocks in US for June 2025 - Yahoo Finance
Capnia Inc stock soars to 52-week high, hits $81.03 By Investing.com - Investing.com Nigeria
Capnia Inc stock soars to 52-week high, hits $81.03 - Investing.com
Soleno Therapeutics Insiders Sell US$39m Of Stock, Possibly Signalling Caution - simplywall.st
Transcript : Soleno Therapeutics, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-10-2025 08 - MarketScreener
Soleno Therapeutics Holds Annual Stockholders Meeting - TipRanks
Transcript : Soleno Therapeutics, Inc.Shareholder/Analyst Call - marketscreener.com
Trading (SLNO) With Integrated Risk Controls - news.stocktradersdaily.com
Soleno Therapeutics’ SWOT analysis: vykat xr launch propels stock amid rare disease market potential - Investing.com India
Stifel maintains Soleno Therapeutics stock Buy rating, $108 target - Investing.com
Stifel maintains Soleno Therapeutics stock Buy rating, $108 target By Investing.com - Investing.com India
EMA validates Soleno’s application for Prader-Willi syndrome treatment - Yahoo Finance
(SLNO) Trading Report - news.stocktradersdaily.com
Soleno Therapeutics seeking regulatory approval in treatment of PWS - Yahoo Finance
Sector Update: Health Care Stocks Flat to Lower Pre-Bell Friday - marketscreener.com
Cantor Fitzgerald maintains Overweight on Soleno Therapeutics stock By Investing.com - Investing.com South Africa
Soleno Application for Hyperphagia Treatment in Patients with Prader-Willi Syndrome Gets European Validation - marketscreener.com
Soleno Therapeutics, Inc. (SLNO) Secures EMA Validation for PWS Treatment VYKAT XR - Insider Monkey
Soleno seeks EU approval for Prader-Willi syndrome treatment - Investing.com Australia
Soleno seeks EU approval for Prader-Willi syndrome treatment By Investing.com - Investing.com Canada
Soleno Therapeutics' (SLNO) MAA for PWS Treatment Validated by EMA | SLNO Stock News - GuruFocus
Soleno Therapeutics Announces Submission and EMA Validation - GlobeNewswire
Soleno's PWS Drug VYKAT Advances in Europe After Recent FDA ApprovalKey Details for Investors - Stock Titan
BCE Inc: Stock Forecast & Analysis - The Globe and Mail
Buy AT&T or Verizon Stock if Market Volatility Resurges? - The Globe and Mail
Cantor Fitzgerald maintains Overweight on Soleno Therapeutics stock - Investing.com Australia
Soleno Therapeutics to Participate in Upcoming June Conferences - GlobeNewswire
Lowe’s Stock Uptrend Can Continue for These 2 Reasons - The Globe and Mail
Rare Disease Leader Soleno Therapeutics Secures Speaking Slots at Major Healthcare Conferences - Stock Titan
Piper Sandler maintains $145 target on Soleno Therapeutics stock - Investing.com Australia
Soleno reports positive VYKAT XR results for Prader-Willi syndrome By Investing.com - Investing.com South Africa
Piper Sandler maintains $145 target on Soleno Therapeutics stock By Investing.com - Investing.com Canada
Soleno reports positive VYKAT XR results for Prader-Willi syndrome - Investing.com Australia
Soleno Therapeutics (SLNO) Reports Promising Vykat XR Study Resu - GuruFocus
Soleno Therapeutics (SLNO) Reports Promising Vykat XR Study Results | SLNO Stock News - GuruFocus
Soleno Therapeutics Presents Positive Clinical Data for VYKAT™ XR at the 2025 Pediatric Endocrine Society Annual Meeting - Nasdaq
Soleno Therapeutics Announces Data Presentation Showing that Resumption of Treatment with VYKAT(TM) XR after a Randomized Withdrawal Period was Associated with Significant Improvements in Hyperphagia and Behavioral Symptoms in Participants wi - The Manila Times
VYKAT XR Clinical Data Shows Major Improvements in Prader-Willi Syndrome Symptoms | SLNO Stock News - Stock Titan
Soleno Therapeutics, Inc. (NASDAQ:SLNO) Receives Average Recommendation of “Buy” from Brokerages - Defense World
Company News for May 19, 2025 - The Globe and Mail
Northern Trust Corp Buys 34,309 Shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO) - Defense World
Soleno Therapeutics Announces Presentations Featuring VYKAT(TM) XR in Prader-Willi Syndrome at PES 2025 - GlobeNewswire
Soleno Therapeutics Inc (SLNO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Soleno Therapeutics Inc 주식 (SLNO) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Hirano Patricia C | SEE REMARKS |
Jun 24 '25 |
Sale |
84.25 |
266 |
22,410 |
17,036 |
1.11%
1.70%
자본화:
|
볼륨(24시간):